News Releases
Viewing Category: HIV Aids
-
MONTREAL, CANADA — February 7, 2008
CASTLE Study Showed Similar Efficacy Between Once-Daily Reyataz® (atazanavir sulfate)/Ritonavir and Twice-Daily Lopinavir/Ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
Data also showed differences in gastrointestinal and lipid effects between REYATAZ/ritonavir and lopinavir/ritonavir among study population
-
MONTREAL, CANADA — May 17, 2007
Health Canada Approves Reyataz® (atazanavir sulfate) 300 mg Single Capsule Formulation in Combination Therapy for Adults With HIV-1 Infection
Formulation Marks The First One Capsule, Once Daily Protease Inhibitor Dosing Option for Use With Ritonavir In Appropriate Patients
-
PRINCETON, N.J. and FOSTER CITY, Calif. - September 28, 2006
Bristol-Myers Squibb and Gilead Sciences establish agreement to commercialize Atripla™ (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Canada
If Approved, Product Would Be the First Once-Daily Single Tablet Regimen for HIV-1 Infection in Adults in Canada
